XIAP Deficiency Could Lead to Microbiota Alterations

A team of scientists at the Dresden University of Technology has reported that XIAP (X-linked Inhibitor of Apoptosis Protein) deficiency is associated with defects in Paneth cells—leading to microbe-triggered intestinal inflammation. Their findings were published in Science Immunology. 

 “The interplay of genetics and the environment makes IBD a very complex disease. Also, a particularly challenging one to study,” says Sebastian Zeissig, research group leader. “Paneth cells are crucial for controlling the microbiome. These cells produce small molecules that act as antibiotics,” he added. Without a functional XIAP gene, Paneth cells could not produce and release antimicrobial molecules to the same extent. This, in turn, led to an imbalance in the microbiome.

After observing that loss of the XIAP gene led to damage in Paneth cells and imbalance in the microbiome, the researchers re-introduced antimicrobial molecules, similar to those produced by healthy Paneth cells, to mice with the genetic defect. The molecules were able to prevent intestinal inflammation, even in the presence of disease-causing bacteria.

These results suggest potential new opportunities for personalized IBD therapies. “It remains to be seen if the antimicrobial molecules could be a potential therapeutic option—not only for the individuals with XIAP deletions but also with other IBD-linked genetic defects that disrupt Paneth cells,” Zeissig concluded.